Navegar por autor "Salgado Fernández, Mercedes"

A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond

2014- Salgado Fernández, Mercedes

A phase II study of capecitabine in combination with erlotinib as first-line therapy in patients with metastatic pancreatic cancer (stage IV)

2011- Reboredo Lopez, Margarita; Candamio Folgar, Sonia; López López, Rafael; Quintero Aldana, Guillermo; Salgado Fernández, Mercedes; [et al.]

Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program

2015- Salgado Fernández, Mercedes

Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of KRAS wild-type metastatic colorectal cancer: Final results of a phase II open-label clinical trial

2013- Quintero Aldana, Guillermo; Salgado Fernández, Mercedes

Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: Final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study)

2014- Quintero Aldana, Guillermo; Salgado Fernández, Mercedes

Clinical guideline SEOM: hepatocellular carcinoma

2015- Salgado Fernández, Mercedes

Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain.

2017-06- Hidalgo, M.; Álvarez, R.; Gallego, J.; Guillen_Ponce, C.; Laquente, B.; [et al.]

Correlation between RECIST-conventional imaging techniques, morphologic response by CT and histopathologic response, in hepatic metastasis secondary to colorectal cancer: The AVAMET study.

2015- Salgado Fernández, Mercedes

Correlation of RECIST, Computed Tomography Morphological Response, and Pathological Regression in Hepatic Metastasis Secondary to Colorectal Cancer: The AVAMET Study.

2020- Vera, Ruth; Gómez, María Luisa; Ayuso, Juan Ramón; Figueras, Joan; García-Alfonso, Pilar; [et al.]

Decisiones terapéuticas en el tratamiento del carcinoma hepatocelular y patrones de uso de sorafenib. Resultados del estudio internacional observacional GIDEON en España

2015- Fernandez Castroagudin, Javier; Turnes Vázquez, Juan; Salgado Fernández, Mercedes; Martín-Granizo Barrenechea, Ignacio

Early venous thromboembolism is associated with worse prognosis in advanced pancreatic cancer.

2015- Salgado Fernández, Mercedes

Effectiveness of gemcitabine and capecitabine in advanced colorectal cancer patients: A retrospective analysis

2012- Quintero Aldana, Guillermo; Salgado Fernández, Mercedes

Efficacy and safety of FOLFIRI/Aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after the failure of an oxaliplatin-based regimen

2019- Martinez Lago, Nieves Purificacion; Carmona Campos, Marta; Gonzalez Villarroel, P; Salgado Fernández, Mercedes; De La Cámara Gómez, Juan Cruz; [et al.]

Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers

2019- Fernández Montes, Ana; Martinez Lago, Nieves Purificacion; Covela Rúa, Marta; De La Cámara Gómez, Juan Cruz; González Villaroel, Paula; [et al.]

Erlotinib as frontline treatment for elderly patients with advanced non-small-cell lung cancer (NSCLC) and non-squamous histology - Results of a galician lung cancer group (GGCP044/09 study) grupo galego de cancro de pulmon (GGCP)

2011- Firvida Perez, Jose Luis; Fernández Montes, Ana; Vázquez Estévez, Sergio; Varela Ferreiro, Silvia; Campos Balea, Begoña; [et al.]

Evaluación económica de capecitabina + cisplatino frente a 5-FU + cisplatino en el tratamiento en primera linea de cancer gastrico avanzado en España

2011- Salgado Fernández, Mercedes

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ?3 circulating tumour cells: the randomised phase III VISNÚ-1 trial

2020- Aranda, Enrique; Viéitez, Jose Maria; Gómez-España, Auxiliadora; Gil Calle, Silvia; Salud-Salvia, Antonieta; [et al.]

Gemcitabine and Capecitabine as Third- or Later-line Therapy for Refractory Advanced Colorectal Cancer: A Retrospective Study

2013- Valladares Ayerbes, Manuel; Reboredo Lopez, Margarita; Fernández Montes, Ana; Varela Ferreiro, Silvia; Quintero Aldana, Guillermo; [et al.]

Incidence of venous thromboembolism (VTE) and Khorana's score (KS) in ambulatory high-grade glioma (HGG) patients receiving chemotherapy

2015- Salgado Fernández, Mercedes

Meta-Analysis of Mismatch Repair Polymorphisms within the Cogent Consortium for Colorectal Cancer Susceptibility

2013- Cubiella Fernández, Joaquín; Carracedo Álvarez, Ángel; Fernández Rozadilla, Ceres; Ruiz Ponte, Clara; Sánchez Hernández, Eloy; [et al.]

Repositorio digital RUNA

Navegar por autor "Salgado Fernández, Mercedes"

A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond ﻿

A phase II study of capecitabine in combination with erlotinib as first-line therapy in patients with metastatic pancreatic cancer (stage IV) ﻿

Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program ﻿

Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of KRAS wild-type metastatic colorectal cancer: Final results of a phase II open-label clinical trial ﻿

Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: Final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study) ﻿

Clinical guideline SEOM: hepatocellular carcinoma ﻿

Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. ﻿

Correlation between RECIST-conventional imaging techniques, morphologic response by CT and histopathologic response, in hepatic metastasis secondary to colorectal cancer: The AVAMET study. ﻿

Correlation of RECIST, Computed Tomography Morphological Response, and Pathological Regression in Hepatic Metastasis Secondary to Colorectal Cancer: The AVAMET Study. ﻿

Decisiones terapéuticas en el tratamiento del carcinoma hepatocelular y patrones de uso de sorafenib. Resultados del estudio internacional observacional GIDEON en España ﻿

Early venous thromboembolism is associated with worse prognosis in advanced pancreatic cancer. ﻿

Effectiveness of gemcitabine and capecitabine in advanced colorectal cancer patients: A retrospective analysis ﻿

Efficacy and safety of FOLFIRI/Aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after the failure of an oxaliplatin-based regimen ﻿

Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers ﻿

Erlotinib as frontline treatment for elderly patients with advanced non-small-cell lung cancer (NSCLC) and non-squamous histology - Results of a galician lung cancer group (GGCP044/09 study) grupo galego de cancro de pulmon (GGCP) ﻿

Evaluación económica de capecitabina + cisplatino frente a 5-FU + cisplatino en el tratamiento en primera linea de cancer gastrico avanzado en España ﻿

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ?3 circulating tumour cells: the randomised phase III VISNÚ-1 trial ﻿

Gemcitabine and Capecitabine as Third- or Later-line Therapy for Refractory Advanced Colorectal Cancer: A Retrospective Study ﻿

Incidence of venous thromboembolism (VTE) and Khorana's score (KS) in ambulatory high-grade glioma (HGG) patients receiving chemotherapy ﻿

Meta-Analysis of Mismatch Repair Polymorphisms within the Cogent Consortium for Colorectal Cancer Susceptibility ﻿

A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond

A phase II study of capecitabine in combination with erlotinib as first-line therapy in patients with metastatic pancreatic cancer (stage IV)

Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program

Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of KRAS wild-type metastatic colorectal cancer: Final results of a phase II open-label clinical trial

Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: Final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study)

Clinical guideline SEOM: hepatocellular carcinoma

Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain.

Correlation between RECIST-conventional imaging techniques, morphologic response by CT and histopathologic response, in hepatic metastasis secondary to colorectal cancer: The AVAMET study.

Correlation of RECIST, Computed Tomography Morphological Response, and Pathological Regression in Hepatic Metastasis Secondary to Colorectal Cancer: The AVAMET Study.

Decisiones terapéuticas en el tratamiento del carcinoma hepatocelular y patrones de uso de sorafenib. Resultados del estudio internacional observacional GIDEON en España

Early venous thromboembolism is associated with worse prognosis in advanced pancreatic cancer.

Effectiveness of gemcitabine and capecitabine in advanced colorectal cancer patients: A retrospective analysis

Efficacy and safety of FOLFIRI/Aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after the failure of an oxaliplatin-based regimen

Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers

Erlotinib as frontline treatment for elderly patients with advanced non-small-cell lung cancer (NSCLC) and non-squamous histology - Results of a galician lung cancer group (GGCP044/09 study) grupo galego de cancro de pulmon (GGCP)

Evaluación económica de capecitabina + cisplatino frente a 5-FU + cisplatino en el tratamiento en primera linea de cancer gastrico avanzado en España

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ?3 circulating tumour cells: the randomised phase III VISNÚ-1 trial

Gemcitabine and Capecitabine as Third- or Later-line Therapy for Refractory Advanced Colorectal Cancer: A Retrospective Study

Incidence of venous thromboembolism (VTE) and Khorana's score (KS) in ambulatory high-grade glioma (HGG) patients receiving chemotherapy

Meta-Analysis of Mismatch Repair Polymorphisms within the Cogent Consortium for Colorectal Cancer Susceptibility